BioBridgeX
Log inCompare quotes
CMC / Manufacturing

QC & Release Testing CDMOs

Free for buyersNeutral marketplace
Quick answer

QC and release testing is the GMP-grade analytical work that decides whether a manufactured batch can be dosed in patients, checking identity, potency, purity, sterility, and endotoxin against an approved specification. You need it once material is made under GMP, from first clinical batch through commercial supply. On BioBridgeX, buyers source and compare qualified CDMOs and release labs in one place, free for buyers.

QC & Release Testing CDMOs on BioBridgeX

We are qualifying and publishing QC & Release Testing CDMOs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is QC & Release Testing and when do you need it?

QC and release testing is the analytical gate every batch has to pass before it can be dosed in a patient. A manufacturer makes drug substance or drug product, then a quality control lab runs the batch against an approved specification: a defined list of tests, methods, and acceptance criteria. Every result has to fall inside the limits, the batch record has to be reviewed, and a quality unit (in the EU, a Qualified Person) has to sign the release before the material can ship or go into a trial. No clean release, no dosing. That is the whole point of the workstream.

The release panel depends on the product, but the spine is consistent. Identity confirms the molecule is what the label says. Assay and potency confirm strength, whether that is an HPLC content assay for a small molecule or a cell-based bioassay for a biologic. Purity and impurities cover related substances, aggregates, residual solvents, host-cell protein and DNA, and process residuals. For sterile products you add the safety tests: sterility (USP <71> or EP equivalent), bacterial endotoxin (USP <85>, typically LAL), bioburden, and container-closure integrity. Appearance, pH, osmolality, particulate matter, and uniformity round out a typical drug-product spec.

You need release testing the moment material is made under GMP, which for most programs is the first clinical batch, and it never stops after that. The same discipline carries through Phase 1 supply, scale-up, registration batches, and routine commercial release, with the specification tightening and the methods getting formally validated as the program matures. Early development assays can run non-GMP, but anything that releases material for a human has to run under GMP with validated, often compendial, methods. Plan release testing as a recurring obligation, not a one-time event, because every campaign generates batches that each need their own certificate of analysis.

What does a QC & Release Testing CDMO actually do?

A release lab does more than run instruments. It develops or transfers the methods, validates them to ICH Q2 expectations, qualifies reference standards, runs the release panel under GMP, and issues a certificate of analysis the sponsor or its Qualified Person relies on to release the batch. Many of these suppliers are the analytical arm of a CDMO that also makes the material, but a large share of the market is standalone contract QC labs that test product made elsewhere, which is common when a sponsor wants an independent lab or a second site for redundancy.

Two pieces of the work decide whether a program runs smoothly, and both happen before any routine batch is tested. The first is method transfer: moving a validated method from your development lab or your drug-substance site into the release lab so it performs the same way in their hands, with a documented transfer protocol and acceptance criteria. The second is handling the result that falls outside the limit. A good lab runs a disciplined out-of-specification (OOS) investigation under a Phelps-style root-cause process, distinguishes a real failure from a lab error, and documents it so the conclusion holds up in an inspection. How a supplier handles an OOS tells you more about them than a clean run ever will.

  • Identity and strength: HPLC or UPLC assay, mass spec, peptide mapping, cell-based or binding potency assays for biologics
  • Purity and impurities: related substances, aggregates (SEC), charge variants, residual solvents (GC headspace), host-cell protein and residual DNA, elemental impurities (ICP-MS)
  • Sterility and safety: sterility (USP <71> / EP 2.6.1), bacterial endotoxin (USP <85> LAL), bioburden, mycoplasma and adventitious agents for biologics
  • Physical and container tests: appearance, pH, osmolality, sub-visible particulates, uniformity of dosage units, container-closure integrity (CCIT)
  • Method work: method development, validation to ICH Q2, method transfer and verification, forced-degradation and specificity studies
  • Quality deliverables: GMP certificate of analysis, OOS and OOT investigations, reference standard qualification, stability-indicating method support

How to choose a QC & Release Testing CDMO?

Two filters do most of the work: does the lab have the right GMP quality grade and inspection history for where you plan to file, and does it actually run your kind of method on your kind of product. A lab that releases small-molecule oral solids every day may be a poor fit for a cell-based potency assay or a viral-vector release panel. Match the assay menu and the modality first, then look at capacity, turnaround, and how the lab behaves when a result goes sideways. Sterility and endotoxin results in particular sit on the critical path to release, so a realistic turnaround on those tests, not the headline price, is often what determines when your batch ships.

Run a short checklist before you commit. The cost of choosing wrong here is not a bad quote, it is a held batch, a failed transfer, or a finding you cannot defend in an inspection.

  • Quality and GxP status: confirm GMP certification, the inspection history, and which agencies (FDA, EMA, PMDA) have audited the site, since you need to cite this lab in a filing
  • Capacity and lead time: ask for realistic turnaround on the rate-limiting tests (sterility runs 14 days, endotoxin and bioburden have their own queues) and whether they have an open slot for your batch schedule
  • Modality and indication fit: confirm the lab runs your specific methods (cell-based potency, peptide mapping, AAV titer, residual testing) routinely, not as a stretch
  • Region and regulatory track record: match the lab to where you will release and file, and check it can support Qualified Person release for EU supply if you need it
  • Data quality and integrity: validated methods to ICH Q2, sound method-transfer protocols, a disciplined OOS process, and data-integrity controls that survive an audit
  • IP and confidentiality: clear terms on your methods, specifications, and results, and confidentiality on a product or indication you may not want disclosed

Frequently asked questions

What is the difference between QC release testing and stability testing?
Release testing confirms a batch meets its specification at the moment you release it, so it can be dosed or shipped. Stability testing tracks the same batch over time, held at controlled temperature and humidity, to establish shelf life and a retest date. They share many of the same methods (assay, purity, related substances), but release is a one-time pass-or-fail gate per batch, while stability is a scheduled program that pulls samples at intervals for months or years. Most sponsors source both, often from the same lab so the methods stay consistent.
Does QC and release testing have to be done under GMP?
Yes, for any material that will be dosed in a human. Release testing falls under GMP (Good Manufacturing Practice), the same quality system that governs the manufacturing, and the methods generally have to be validated to ICH Q2. Early development and characterization assays can run non-GMP before you transition, but the panel that actually releases a clinical or commercial batch must run under GMP with a quality unit reviewing and signing off. GMP here is distinct from the GLP that governs your tox studies and the GCP that governs the clinic.
How long does batch release testing take?
It depends on the panel, but sterility is almost always the rate-limiter. A compendial sterility test (USP <71>) runs a 14-day incubation, so even when every other test is fast, a sterile product cannot be released until that read is complete unless you have a validated rapid microbiological method. Endotoxin, bioburden, and chemistry tests are quicker but have their own queues. When you scope a release lab, ask for turnaround on the slowest test on your spec and schedule backward from your dosing date, because that is what sets your real release timeline.
What happens when a release test result is out of specification (OOS)?
The lab runs a formal OOS investigation before anything is released or rejected. The first step is a laboratory investigation to rule out an assignable cause such as analyst error, equipment fault, or a sample problem. If no lab error is found, the investigation extends to manufacturing to look for a true product failure. The batch cannot be released on a passing retest alone; the conclusion has to be documented and scientifically sound. How a lab handles OOS is one of the best signals of its quality maturity, and it is worth asking about before you sign.
Can I use an independent lab to release product made at a different CDMO?
Yes, and many sponsors do. Standalone contract QC labs routinely test and release product manufactured elsewhere, which is common when you want an independent release lab, a second site for redundancy, or a specialist for one assay your manufacturing CDMO does not run in-house. The key is a clean method transfer so the release lab reproduces your validated methods, plus clear agreement on who owns the certificate of analysis and the final release decision. On BioBridgeX you can source the release lab separately from the manufacturer and still contract once.
Who can release a batch for the clinic or market?
The release decision sits with the sponsor's quality unit. In the EU and UK, a named Qualified Person (QP) has to certify each batch before it can be used in a trial or sold, a legal role with personal accountability. In the US there is no QP equivalent, but a quality unit must review the batch record and release results against the specification before the batch is dosed or distributed. The contract lab generates and reports the data; the release sign-off is a quality-unit responsibility, so confirm up front whether you need QP release for EU supply.

Source QC & Release Testing with one contract

Compare transparent quotes from qualified QC & Release Testing CDMOs, then contract once. Free for buyers.

Compare quotes